Zeltiq

Zeltiq was founded to commercialize technology based on research demonstrating that fat cells are more susceptible than other types of cells to extreme cold and can be selectively, painlessly and permanently destroyed in a process known as cryolipolysis. With FDA 510(k) clearance for its CoolSculpting system in hand in early September, Zeltiq hopes to lead the charge into the body contouring aesthetics frontier with a technology that it believes stands apart from emerging laser, radiofrequency and ultrasound systems.

More from Archive

More from Medtech Insight